Status:
COMPLETED
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
Lead Sponsor:
Pfizer
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.
Eligibility Criteria
Inclusion
- Locally advanced or metastatic HCC
- Failure of one prior antiangiogenic therapy including sorafenib, bevacizumab and brivanib.
- Child-Pugh Class A or B (score 7 only) disease.
Exclusion
- Prior treatment of advanced HCC with more than one prior first-line systemic therapy.
- Any prior local therapy within 2 weeks of starting the study treatment.
- Presence of hepatic encephalopathy and/or clinically relevant ascites.
- Presence of main portal vein invasion by HCC.
Key Trial Info
Start Date :
December 6 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2016
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT01210495
Start Date
December 6 2010
End Date
December 20 2016
Last Update
January 9 2019
Active Locations (77)
Enter a location and click search to find clinical trials sorted by distance.
1
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, United States, 94704
2
UCSD Medical Center- La Jolla
La Jolla, California, United States, 92037
3
Moores UCSD Cancer Center
La Jolla, California, United States, 92093
4
University of California Irvine Medical Center
Orange, California, United States, 92868